In a study of 135 breast cancer patients, Sainsbury et al. demonstrated that EGFR, among different variables, is the single most important determinant of overall and relapse-free survival in lymph node-negative patients.29 Battaglia et al. also observed patients with metastatic breast tumors and axillary lymph node involvements are more likely to be EGFR+.30 This evidence concerns the gene EGFR and breast carcinoma.